Durable complete response to sintilimab plus chemotherapy in gallbladder cancer with extensive metastasis: A case report

Figure 1 Summary of disease course and treatment procedure.

Figure 2 Preoperative and postoperative imaging examinations and primary tumor pathological staining results. A: Preoperative contrast-enhanced computer tomography (October 22, 2019) shows a soft tissue mass (arrow) in the gallbladder suggestive of gallbladder cancer; B: Hematoxylin and eosin staining of the primary tumor (× 100); C: Hematoxylin and eosin staining of the primary tumor (× 200); D: Postoperative contrast-enhanced magnetic resonance imaging (November 19, 2019) following radical gallbladder resection reveals no evidence of tumor recurrence.

Figure 3 Computer tomography scans obtained on March 25, 2020, demonstrating extensive metastatic disease after surgery. A-C: Diffuse liver metastases; D and E: Lung metastases; F: Retroperitoneal lymph nodes.

Figure 4 Computer tomography evaluation after two cycles of first line treatment of sintilimab plus chemotherapy (May 18, 2020), assessed as partial response. A-C: Liver metastases reduced in size and number; D and E: Lung metastases reduced in size and number; F: Retroperitoneal metastatic lymph nodes reduced in size.

Figure 5 Computer tomography evaluation indicates complete response (September 16, 2021) during maintenance therapy. A-C: Disappearance of liver metastases; D and E: Disappearance of pulmonary metastases; F: Disappearance of retroperitoneal lymph nodes.